Drugs / TRC093
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00492830 | Jun 2007 → Nov 2009 | cancer, metastatic neoplasm | Tracon Pharmaceuticals Inc. | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TRC093 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00492830 ↗ |
| Known as | MT-293 | ChEMBL registry synonym — accepted as the source's own label CHEMBL2109374 ↗ |
| Action | Inhibit | “Collagen alpha-4(IV) chain inhibitor” CHEMBL2109374 ↗ |
| Modality | Monoclonal antibody | “humanized monoclonal antibody” NCT00492830 ↗ |
| Route | Intravenous | “administered i.v.” NCT00492830 ↗ |
| Target | COL4A4 | “Collagen alpha-4(IV) chain inhibitor” CHEMBL2109374 ↗ |